A molecular basis for selective antagonist destabilization of dopamine D3 receptor quaternary organization by Marsango, Sara et al.
1Scientific RepoRts | 7: 2134  | DOI:10.1038/s41598-017-02249-3
www.nature.com/scientificreports
A Molecular Basis for Selective 
Antagonist Destabilization of 
Dopamine D3 Receptor Quaternary 
Organization
Sara Marsango1, Gianluigi Caltabiano2, Mireia Jiménez-Rosés2, Mark J. Millan3,  
John D. Pediani1, Richard J. Ward1 & Graeme Milligan1
The dopamine D3 receptor (D3R) is a molecular target for both first-generation and several recently-
developed antipsychotic agents. Following stable expression of this mEGFP-tagged receptor, Spatial 
Intensity Distribution Analysis indicated that a substantial proportion of the receptor was present 
within dimeric/oligomeric complexes and that increased expression levels of the receptor favored a 
greater dimer to monomer ratio. Addition of the antipsychotics, spiperone or haloperidol, resulted in 
re-organization of D3R quaternary structure to promote monomerization. This action was dependent 
on ligand concentration and reversed upon drug washout. By contrast, a number of other antagonists 
with high affinity at the D3R, did not alter the dimer/monomer ratio. Molecular dynamics simulations 
following docking of each of the ligands into a model of the D3R derived from the available atomic level 
structure, and comparisons to the receptor in the absence of ligand, were undertaken. They showed 
that, in contrast to the other antagonists, spiperone and haloperidol respectively increased the atomic 
distance between reference α carbon atoms of transmembrane domains IV and V and I and II, both of 
which provide key interfaces for D3R dimerization. These results offer a molecular explanation for the 
distinctive ability of spiperone and haloperidol to disrupt D3R dimerization.
Dopamine receptors are G protein-coupled receptors (GPCRs) that belong to the class A sub-family1. They 
co-ordinate many functions, including motor control, emotional responsiveness and memory consolidation1. 
Moreover, dysregulation of dopaminergic neuro-transmission is implicated in multiple disorders including 
Parkinson’s disease and a broad suite of psychotic disorders, including schizophrenia1–3.
Although class A GPCRs are encoded by single polypeptides that span the plasma membrane seven times and 
can certainly function as monomeric species4, many of these, including the dopamine receptor subtypes, have 
been shown to form both homo-5–10 and hetero-dimers/oligomers8, 11–15 both in vitro and in vivo and this may 
have functional and clinical significance. Rather less work in this context has focused on the dopamine D3 recep-
tor (D3R) subtype, which is enriched in limbic areas of the brain and a target for the treatment of, for example, 
drug addiction and the cognitive and social deficits of schizophrenia and other psychiatric disorders16, 17. Even in 
early studies the potential for dimeric/oligomeric arrangement of this receptor in rodent brain tissue was high-
lighted18, as well as in more recent studies in transfected cell lines that have focused on the extent and basis of such 
interactions2, 8, 19, 20. By combining molecular modelling, site direct-mutagenesis and homogenous time-resolved 
Fluorescence Resonance Energy Transfer (htr-FRET) techniques, interfaces that allow such interactions have 
been defined, resulting in description of homomeric quaternary structures of this receptor that involve two dis-
tinct dimeric species, as well as a rhombus-shaped tetramer20. Unlike members of the class C GPCR sub-family 
that function as obligate dimers/oligomers4, quaternary complexes of the D3R are not generated and maintained 
by covalent interactions between receptor monomers20, indicating that the extent of D3R dimerization and/or 
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oligomerization will likely be governed by both receptor expression level, ligand availability, and the intrinsic 
avidity of these protein-protein interactions. This implies that the observed proportions of receptor monomers, 
dimers and oligomers may well vary between individual cells and tissues and, furthermore, the binding of dis-
tinct ligand chemotypes may selectively alter this if they either differentially regulate receptor expression levels or 
stabilize distinct states of the receptor. Given roles of segments of the seven transmembrane domains (TMDs) of 
GPCRs that are located close to the extracellular face in controlling class A receptor dimerization4, 20, 21 it is clearly 
possible that different antagonist/inverse agonist-bound structures of the same GPCR may alter the dimerization 
potential or propensity of the receptor and, therefore, the steady-state distribution of monomers, dimers and 
oligomers.
Herein we test this hypothesis using the D3R for which high affinity blockers from distinct chemotypes are 
available. Moreover, as an atomic level structure of the D3R bound to the ligand eticlopride is available22 and 
substantial efforts have been made to predict modes of binding of other antagonist ligands23, this provided a 
framework with which to assess the outcomes. To answer such questions, we have employed Spatial Intensity 
Distribution Analysis (SpIDA)24–27 as this technique can be used to assess the steady-state proportion of mono-
mers, dimers/oligomers of a cell surface receptor tagged with an appropriate fluorophore, by interrogation and 
statistical analysis of Regions of Interest (RoI) within confocal images of cells expressing such a receptor24–27. We 
report three key set of outcomes. Firstly, the proportion of the D3R present within dimers/oligomers is increased 
by enhancing levels of receptor expression by treatment of cells expressing the D3R with sodium butyrate. 
Secondly, exposure to some, but not all, chemotypes of ligand with D3R antagonist properties markedly reduces 
the steady-state proportion of D3R within dimeric/oligomeric complexes, and thirdly, application of molecu-
lar dynamics simulations indicates selective alterations in the tertiary structure of D3R caused by ligands that 
reduce D3R quaternary structure complexity and that these are consistent with previously defined key dimer and 
tetramer-forming interfaces.
Results
SpIDA can distinguish between monomer and dimer forms of hD3R-mEGFP. In preparation for 
studies to assess the steady-state distribution between monomeric and dimeric/oligomeric states of the human 
(h)D3R we expressed constitutively in Flp-In T-REx 293 cells a form of this GPCR tagged at the C-terminus with 
monomeric, Ala206Lys, enhanced green fluorescent protein (mEGFP)28. A number of distinct clones expressing 
this construct were then isolated. Resolution by SDS-PAGE of cell lysates from three clones, followed by immu-
noblotting with an anti-GFP antiserum, showed a similar pattern in which the predominant form was a polypep-
tide of some 60 kDa (Fig. 1a). Parallel ligand binding studies using the dopamine D2/D3 receptor antagonist [3H]
spiperone provided quantitative validation in that the level of the hD3R-mEGFP construct was highest in clone 
2 and that there was a trend towards higher levels of the receptor in clone 8 compared to clone 6 (Fig. 1b). This 
profile was confirmed in the plasma membrane of these cells by observing confocal images (Fig. 1c). Fluorescence 
intensity analysis of images of the basolateral surface of these clones allowed estimation of expression levels as 
receptors per μm2 (Fig. 1d) that was qualitatively similar to those generated from the specific [3H]spiperone 
binding studies. Overall, these initial studies defined a rank order of expression of the hD3R as clone 2 > clone 
8 ≥ clone 6 and that the receptor was located predominantly at the cell surface.
To be able to define the quaternary structure of hD3R within these clones we initially employed control 
SpIDA24–27 studies on Flp-In T-REx 293 cells induced to express differing levels of a single molecule of mEGFP 
that was targeted to the plasma membrane by N-terminal addition of a palmitoylation + myristoylation (P + M) 
sequence27. Levels of P + M-mEGFP could be varied by addition of different concentrations of doxycycline 
because the fluorescent protein construct is inserted into a genomic locus from which expression is controlled by 
this antibiotic in a regulated manner29. Using two concentrations of doxycycline that resulted in different levels 
of P + M-mEGFP expression, SpIDA could be applied effectively on confocal images obtained at 2% laser power 
only at the higher level of expression. However, at the lower expression level this could also be achieved success-
fully by increasing laser power to 6% (Fig. 2a). Following treatment with 2 ng.ml−1 doxycycline and with laser 
power set at 2%, analysis of a large number of RoI produced quantal brightness (QB) values for the mEGFP con-
struct of 11.01 ± 0.21 units (mean ± S.E.M., n = 4 × 44, different biological experiments × RoI examined in each 
experiment) with mean expression level 130 ± 2.5 molecules per μm2. As mEGFP is intrinsically monomeric28, 
then in subsequent studies performed at 2% laser power a measured QB for receptor proteins tagged with mEGFP 
of 11.01 units was defined to represent 1.00 Monomeric Equivalent Units (MEU). Using a similar approach fol-
lowing induction of the cells with 0.75 ng.ml−1 doxycycline, and now using 6% laser power, QB of this construct 
was 24.31 ± 0.31 units (mean ± S.E.M., n = 4 × 44) and when using 6% laser power in subsequent experiments 
QB = 24.31 was also defined as being equivalent to 1.00 MEU. Here expression levels, 68 ± 1.3 molecules per μm2 
(mean ± S.E.M., n = 4 × 44), were approximately half of those obtained following induction with the higher con-
centration of doxycycline (Fig. 2b). Analysis of the full data set showed these to be distributed in Gaussian fashion 
with MEU of 0.994 ± 0.206 (mean ± S.D., n = 352) (Fig. 2c). This indicates that across the range of expression 
levels achieved P + M-mEGFP was routinely observed as being monomeric and even at higher levels of expres-
sion molecular proximity did not produce artefacts that resulted in this construct being identified incorrectly as 
being dimeric. The mean + 2 × S.D. corresponded to 1.406 MEU (Fig. 2b) and represents 95.44% of the dataset. 
In subsequent studies on hD3R-mEGFP QB values above 1.406 MEU were thus taken to represent RoI in which 
dimeric/oligomeric forms were predominant whilst MEU values less than or equal to 1.406 MEU were considered 
to represent regions in which monomers were the dominant species (see ‘Experimental’ for further details).
Confocal images from the basolateral membrane of cells of clones 2, 6 and 8 were now analysed at 6% laser 
power. RoIs from each provided fluorescence intensity data on the oligomeric state of hD3R-mEGFP. For this 
specific data set, in clone 2 QB MEU was 1.75 ± 0.09 (mean ± S.E.M., n = 3 × 44) and this was statistically 
greater than in either clone 6 (1.45 ± 0.05, mean ± S.E.M., n = 3 × 44) or in clone 8 (1.41 ± 0.03, mean ± S.E.M., 
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n = 3 × 44) (Fig. 3a and Supplementary Figure 1). In each clone a substantial number of the individual QB values 
were > 1.406 MEU, indicating that, at steady-state, in each clone a significant proportion of hD3R-mEGFP was 
identified as being dimeric/oligomeric. Analysis of QB values for each individual RoI indicated that the propor-
tion in which hD3R-mEGFP was predominantly within dimeric/oligomeric complexes ranged from 75.0 ± 2.3% 
(clone 2), to 47.7 ± 6.0% (clone 6) to 40.2 ± 1.5% (clone 8) (Fig. 3b). Interestingly, the assessed higher proportion 
of hD3R-mEGFP present within dimeric/oligomeric complexes within the basolateral membrane of clone 2 corre-
lated with higher expression levels (59.3 ± 1.4 copies per µm2, mean ± S.E.M., n = 3 × 44), compared to 49.6 ± 2.1 
(clone 8) and 39.2 ± 1.2 (clone 6) copies per µm2 (each mean ± S.E.M., n = 3 × 44) at the basolateral surface of 
cells (Fig. 3c).
Increasing expression levels of hD3R-mEGFP results in a greater extent of receptor dimeriza-
tion. To assess if the proportion of dimeric/oligomeric hD3R-mEGFP could be linked more clearly to expres-
sion levels of the receptor, rather than clonal variability, we treated cells of clone 8 with the histone deacetylase 
inhibitor sodium butyrate which has previously been shown to increase cell surface levels of a number of other 
GPCRs30, 31. Overnight treatment with 20 mM sodium butyrate increased levels of hD3R-mEGFP as assessed 
by each of immunoblotting of cell lysates (Fig. 4a), observation of confocal images of the basolateral surface of 
the cells (Fig. 4b) and assessment of the number of copies of hD3R-mEGFP per μm2 of the basolateral surface 
(80.0 ± 2.0 sodium butyrate, 49.4 ± 2.0 untreated, means ± S.E.M., n = 3 × 44) (Fig. 4c). The increase in levels 
of basolateral membrane receptor produced by treatment with sodium butyrate necessitated subsequent SpIDA 
being performed on images captured at lower laser power (2%) compared to the untreated cells (6%). When 
corrected for the difference in QB of mEGFP obtained under the different laser light intensities (see above and 
Fig. 2), the assessed MEU value of hD3R-mEGFP in the basolateral cell surface was significantly higher in the 
Figure 1. Expression of hD3R-mEGFP. hD3R-mEGFP was expressed constitutively in Flp-In T-REx 293 
cells. Three distinct clones were isolated and characterized. (a) Cell lysates were resolved by SDS-PAGE and 
immunoblotted with an anti-GFP antiserum (upper panel) or an anti-α-tubulin antiserum (lower panel). 
(b) Specific binding of [3H]spiperone (5 nM) was assessed in cell membrane preparations generated from 
each clone. Data from n = 3 experiments, with the average value from each experiment shown, error bars 
represent ± S.E.M, ***p < 0.001 when compared to the indicated clone, ns = not significant. (c) Confocal 
images were collected from the basolateral membrane (c(i)) and across the midsection (c(ii)) of cells. Scale 
bar = 20 μm. (d) Fluorescence intensity analysis of the images akin to those of (c(i)) allowed estimation of 
hD3R-mEGFP expression levels. Combined data from n = 3 experiments, with the average value from each 
experiment shown, error bars represent ± S.E.M, *p < 0.05; **p < 0.01 when compared to the indicated clone, 
ns = not significant.
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sodium butyrate-treated cells (Fig. 4d,e) and this corresponded to a higher proportion of dimeric/oligomeric 
complexes (Fig. 4f).
Some antagonists of hD3R reduce steady-state receptor dimerization. We next assessed if lig-
ands from distinct chemical classes that act as antagonists/inverse agonists of the hD3R could alter receptor 
quaternary organization. Treatment of clone 2 cells for 16 hours with concentrations (10 μM) of spiperone and 
haloperidol (Fig. 5) that were calculated to be at least 100 times their Kd at hD3R (Table 1) had no effect on 
overall expression levels of the receptor (Fig. 6a). This was also the case following treatment with other, struc-
turally distinct (Fig. 5), orthosteric antagonist ligands with affinity at the hD3R including eticlopride, nemon-
apride and clozapine (Fig. 6a). Confocal images of the basolateral membrane of control and either spiperone- or 
haloperidol-treated cells were collected (Fig. 6b) and analysed using SpIDA (Fig. 6c). In haloperidol-treated cells 
the receptor construct now displayed calculated MEU 1.19 ± 0.05 (mean ± S.E.M., n = 3 × 44) (Fig. 6d) which 
was markedly lower (p < 0.01) than untreated cells (MEU 1.49 ± 0.01, mean ± S.E.M., n = 3 × 44 in this specific 
experimental dataset) and analysis of the individual images showed that the receptor was now predominantly 
monomeric (Fig. 6e). Similar effects were produced by treatment with spiperone (average MEU = 1.17 ± 0.03, 
mean ± S.E.M, n = 3 × 44) (Fig. 6c–e). Furthermore, the ability of spiperone to favor monomerization of the 
hD3R was concentration-dependent (Fig. 6f,g).
Figure 2. Determination of monomeric QB. Flp-In T-REx 293 cells harboring P + M-mEGFP were treated 
with 0.75 ng.ml−1 or 2 ng.ml−1 doxycycline (Dox) for 16 h. (a) Confocal images from the basolateral membrane 
of these cells were collected at 6% (i) or 2% (ii) laser power respectively. Scale bar = 20 μm. (b) QB MEU were 
assessed in individual RoI and plotted against the number of P + M-mEGFP per µm2 at the basolateral surface. 
Grey circles, cells treated with 0.75 ng.ml−1 Dox; black circles cells treated with 2 ng. ml−1 Dox. The horizontal 
dotted line (1.406 MEU) corresponds to mean + 2 S.D. Values lower or equal to this (95.44% of the data points) 
were scored as ‘monomeric’ (see ‘Experimental’). Vertical dotted lines provide mean particle number per μm2 
for the two conditions described above. (c) QB MEU values obtained with laser power set at 2% and 6% were 
combined and binned. Analysis indicated values to be normally distributed.
Figure 3. hD3R is present as a mixture of complexes: Complexity increases with receptor expression level. 
(a) Overall organizational state of hD3R-mEGFP, data is expressed as QB MEU value, with the average value 
from each experiment shown. Combined data from n = 3 × 44 (experiments × observations), error bars 
represent ± S.E.M. **p < 0.01 when compared to the indicated clone, ns = not significant. (b) Assessment of 
percentage of RoIs containing predominantly dimers/oligomers (characterized by a value of QB MEU > 1.406). 
Combined data from n = 3 × 44 experiments, error bars represent ± S.E.M. *p < 0.05 when compared to the 
indicated clone, ns = not significant. (c) QB MEU were assessed in individual RoI and plotted against the 
number of hD3R-mEGFP per µm2 at the basolateral cell surface. Light grey circles, cells from clone 6; dark grey 
circles cells from clone 8, black circles, cells from clone 2. Horizontal dotted line represents 1.406 MEU, vertical 
dotted lines provide mean receptor number per μm2 for each clone.
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Interestingly, the effects of the butyrophenones spiperone and haloperidol on hD3R quaternary structure were 
not reproduced by other antagonists with high affinity for the hD3R. Thus, treatment of cells of clone 2 with the 
benzamides eticlopride or nemonapride, which are structurally closely related to each other (Fig. 5), but not 
to either spiperone or haloperidol (Fig. 5), did not alter mean MEU nor in the proportion of RoIs assessed as 
containing predominantly receptor dimers/oligomers versus monomers (Fig. 7). This was also the case for the 
atypical antipsychotic and tricyclic benzodiazepine clozapine (Fig. 7).
Spiperone treatment does not alter the quaternary structure of hD3R-Asp110Ala-mEGFP recep-
tor. To assess whether the effect of spiperone in favoring the monomeric state of hD3R directly reflected direct 
binding of the ligand to the receptor or potentially a non-specific effect at the level of the cell membrane, we 
generated hD3R-Asp110Ala-mEGFP. Alteration of this aspartate residue is known to greatly reduce the affinity of 
the receptor for spiperone32. Expression of hD3R-Asp110Ala-mEGFP in Flp-In T-REx 293 cells was demonstrated 
by confocal microscopy (Fig. 8a) and confirmed by monitoring fluorescence at 520 nm corresponding to mEGFP 
(Fig. 8b) to be at equivalent levels of expression as hD3R-mEGFP (Fig. 8b). Parallel ligand binding experiments 
confirmed that hD3R-Asp110Ala-mEGFP was unable to bind [3H]spiperone (Fig. 8c). SpIDA of images from 
Figure 4. Sodium butyrate increases hD3R expression level and oligomeric complexity. Flp-In T-REx 293 
hD3R-mEGFP clone 8 cells were maintained in the absence (NT) or presence (SB) of 20 mM sodium butyrate 
for 16 h. (a) Lysates from these cells were resolved by SDS-PAGE and immunoblotted with an anti-GFP 
antiserum (upper panel) or an anti-α-tubulin antiserum (lower panel). (b) Confocal images from the basolateral 
membrane of these cells were collected with laser power set at 6% (i) or 2% (ii) respectively. Scale bar = 20 μm. 
(c). Fluorescence intensity analysis of these images indicated hD3R-mEGFP cell surface expression level to be 
higher in cells treated with sodium butyrate. Combined data from n = 3 × 44 (experiments × observations), 
with the average value from each experiment shown, error bars represent ± S.E.M. ***p < 0.001 when 
compared to not treated. (d) QB MEU were assessed in individual RoI and plotted against the number of hD3R-
mEGFP per µm2 at the cell surface. Black circles, untreated cells; grey circles, cells treated with 20 mM sodium 
butyrate. Horizontal dotted line (1.406 MEU), vertical dotted lines provide mean receptor number per μm2 
for not treated and treated. (e) Quaternary arrangement of hD3R-mEGFP expressed as QB MEU value in not 
treated cells (1.38 ± 0.03) and cells treated with sodium butyrate (1.80 ± 0.12). Combined data from n = 3 × 44 
(experiments × observations), error bars represent ± S.E.M., *p < 0.05 when compared to not treated. (f) 
Assessment of percentage of RoIs containing predominantly dimers/oligomers in untreated (43.9 ± 3.3%) and 
sodium butyrate treated (72.7 ± 6.9%) cells. Combined data from n = 3 × 44 (experiments × observations), 
error bars represent ± S.E.M., *p < 0.05 when compared to not treated cells.
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RoIs, assessed at 6% laser power, indicated that at steady-state the percentage of RoIs containing mainly dimers 
/oligomers of hD3R-Asp110Ala-mEGFP was not different from that observed in cells expressing equal levels of 
hD3R-mEGFP (Fig. 8d–f). Treatment of cells expressing hD3R-Asp110Ala-mEGFP with spiperone (10 µM) did 
not, however, alter mean MEU nor the calculated proportion of RoIs containing predominantly receptor dimers/
oligomers (Fig. 8d–f).
The effect of spiperone on hD3R monomerization is reversible but cannot be attributed to 
ligand inverse agonism or ligand-induced differences in receptor mobility. We next explored 
whether ligand-induced monomerization of hD3R was reversible. Initially the dissociation rate of [3H]spiperone 
from hD3R-mEGFP in intact cells at 37 °C was assessed. After allowing binding of [3H]spiperone to reach equi-
librium, washout of unbound ligand allowed dissociation of [3H]spiperone to be followed under conditions of 
infinite dilution. Dissociation of bound [3H]spiperone followed a mono-exponential curve with Koff = 0.014 min−1 
and, therefore, had a half-time in the region of 51 min. After treatment of cells with spiperone for 2 hours to pro-
mote receptor monomerization, the bulk drug was washed out and images collected 4 hours later by which point 
the remaining drug was anticipated to have dissociated from the receptor. Now QB and SpIDA showed that 
receptor complexity had re-established to reach levels of hD3R dimerization that were not statistically different 
from that of untreated cells (Fig. 9a). Although all the ligands employed are functional antagonists of the D3R we 
explored whether ligands that promoted monomerization could be sub-classified on the extent that they acted as 
receptor inverse agonists as regards their G-protein coupling. In Flp-In T-REx 293 cells constitutively expressing 
hD3R and harboring the α subunit of a Cys352Ile, pertussis toxin-resistant, form of Go133, treatment with doxycy-
cline to promote expression of the G protein resulted in enhanced levels of basal [35S]GTPγS binding, and this 
was increased further by addition of 10 μM dopamine (Fig. 9b). Addition of receptor saturating concentrations of 
each of spiperone, haloperidol, eticlopride, nemonapride or clozapine did not significantly reduce the basal level 
of [35S]GTPγS binding (Fig. 9b), indicating that these five antagonists could not be separated based on varying 
degrees of inverse agonism. Ligand-induced alterations in receptor mobility could potentially also affect SpIDA. 
We also employed fluorescence recovery after photobleaching (FRAP) to measure receptor movement, both in the 
unliganded, basal state and in the presence of receptor saturating concentrations of either spiperone or eticlopride 
(Fig. 9c). In the unliganded state, recovery of fluorescence corresponding to hD3R-mEGFP into a RoI followed 
Figure 5. Structure of dopamine receptor antagonists. The chemical structures of the dual D2/D3 orthosteric 
antagonists, spiperone, haloperidol, eticlopride, nemonapride and clozapine are shown.
Compound pKi
Spiperone 8.74 ± 0.08
Haloperidol 7.87 ± 0.15
Eticlopride 10.10 ± 0.26
Nemonapride 9.28 ± 0.49
Clozapine 6.03 ± 0.14
Table 1. Affinity of selective antagonists at hD3R-mEGFP. Values were calculated based on the ability of each 
ligand to compete with [3H]spiperone to bind hD3R-mEGFP.
www.nature.com/scientificreports/
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a mono-exponential with t0.5 = 9.6 ± 0.5 seconds and assessed mobile fraction of 79.4 ± 2.9% (means ± S.E.M., 
n = 11). In the presence of either spiperone or eticlopride the assessed mobile fraction was unaltered, indicating 
that drug treatment did not result in variable detection of hD3R-mEGFP (Fig. 9c). Moreover, the time constant 
for recovery was not different between cells treated with either spiperone or eticlopride.
Ligand docking and molecular dynamics simulations provide a basis for selectivity of ligand 
effects. To provide potential insight into the molecular basis for the distinct effects of spiperone and halop-
eridol versus eticlopride, nemonapride and clozapine on hD3R quaternary organization we turned to the use of 
molecular dynamics simulations. Eticlopride was of particular interest because an atomic level structure of this 
ligand bound to the D3R is available22. We thus compared molecular dynamics simulations of the minimal energy 
state of hD3R bound by each of these ligands (see ‘Experimental’ for further details), alongside the apo-protein, 
and how their binding might affect the organization of the extracellular side of the TMD helices (Fig. 10 and 
Supplemental Figure 2). These showed distinct differences in the orientation of the extracellular face of hD3R 
Figure 6. Antagonist treatment does not alter hD3R-mEGFP expression levels but spiperone and haloperidol 
decrease receptor quaternary complexity. Flp-In T-REx 293 hD3R-mEGFP clone 2 cells were not treated 
(NT) or treated with spiperone (10 µM), haloperidol (10 µM), eticlopride (10 µM), nemonapride (10 µM) or 
clozapine (20 µM) for 16 h. (a) Fluorescence intensity analysis of the basolateral membrane of the untreated 
cells indicated hD3R-mEGFP to be expressed at 68.6 ± 2.0 receptor per µm2 and that treatment with the various 
antagonists did not significantly alter cell surface expression level. Combined data from n = 10 × 44 experiments 
× observations (NT) and 3 × 44 (each antagonist), with the average value from each experiment shown, error 
bars represent ± S.E.M. (b) Confocal images from the basolateral membrane of cells not treated (NT) or treated 
with spiperone or haloperidol were collected with laser power set at 6%. Scale bar = 20 µm. (c) QB MEU were 
assessed in individual RoI and plotted against the number of hD3R-mEGFP per µm2 at the cell surface. Light 
grey circles, untreated cells; dark grey circles, cells treated with haloperidol; Black circles, cells treated with 
spiperone. (d) Quaternary arrangement of hD3R-mEGFP receptor expressed as QB MEU value in not treated 
cells (1.49 ± 0.01) and cells treated with spiperone (1.17 ± 0.03) or haloperidol (1.19 ± 0.05). Combined data from 
n = 3 × 44 measurements, error bars represent ± S.E.M. **p < 0.01 when compared to not treated. (e) Assessment 
of percentage of RoIs containing predominantly dimers/oligomers in untreated (59.1 ± 1.3%) or treated with 
spiperone (18.2 ± 5.7%) or haloperidol (20.5 ± 3.5%). Combined data from n = 3 × 44 experiments, error bars 
represent ± S.E.M., ***p < 0.001 when compared to not treated cells. (f) QB MEU mean values were plotted 
against spiperone concentration. Combined data from n = 44 measurements, error bars represent ± S.E.M. (g) 
The percentage of RoI containing predominantly dimers/oligomers was calculated and plotted against spiperone 
concentration.
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when associated with spiperone and haloperidol compared to when bound by eticlopride, nemonapride or clo-
zapine and also compared to the apo-protein. Analysis of the distances between helices (as measured between 
defined pairs of amino acid α carbon atoms), indicated that whilst both spiperone and haloperidol produced 
marked changes, each ligand stabilized a different inactive conformation of the hD3R. Spiperone-bound hD3R 
induced a significantly increased distance, by 2.3 Å on average, between TMD IV (residue 4.50) and TMD V 
(residue 5.50) (residue numbers reflect the positional reference numbering system introduced by Ballesteros and 
Weinstein)34 compared to the apo-protein (p < 0.01), whereas none of the other ligands induced such a change 
(Fig. 10 and Supplementary Figures 2 and 3). Although not achieving statistical significance, there was also a 
trend for spiperone to induce an increase in the distance between TMD I (residue 1.35) and TMD II (residue 
2.65) and between TMD III (residue 3.40) and TMD VI (residue 6.44). This is interesting since binding of halo-
peridol induced a statistically significant increase of 1.7 Å (p < 0.05) in distance between TMD I (residue 1.35) 
and TMDII (residue 2.65). However, haloperidol did not alter the mean distance between residues 4.50 and 5.50. 
Figure 7. Treatment with eticlopride, nemonapride or clozapine does not alter the quaternary organization of 
hD3R. Flp-In T-REx 293 hD3R-mEGFP clone 2 cells were untreated or treated with eticlopride, nemonapride or 
clozapine as described in Fig. 6. (a) Confocal images from the basolateral membrane of cells not treated (NT) 
or those treated with eticlopride, nemonapride, or clozapine were collected with laser power set at 6%. Scale 
bar = 20 μm. QB MEU were assessed in individual RoI and plotted against the number of hD3R-mEGFP per 
µm2 at the cell surface. Light grey circles, untreated cells (NT); Black circles, cells treated with eticlopride (b(i)), 
nemonapride (c(i)), or clozapine (d(i)). Quaternary organization of hD3R–mEGFP receptor was expressed 
as QB MEU value and was equal to 1.67 ± 0.19 and 1.61 ± 0.13 in vehicle- and eticlopride- treated cells, 
respectively (b(ii)); to 1.44 ± 0.03 and 1.48 ± 0.04 in vehicle- and nemonapride treated cells, respectively (c(ii)) 
and to 1.44 ± 0.04 and 1.41 ± 0.02 in vehicle- and clozapine treated cells, respectively (d(ii)). RoIs containing 
predominantly dimers/oligomers were found to be equal to 68.9 ± 10.0 and 61.4 ± 6.8 in vehicle- and eticlopride 
treated cells, respectively (b(iii)); to 51.5 ± 5.3 and 53.8 ± 7.2 in vehicle- and nemonapride treated cells, 
respectively (c(iii)) and to 50.8 ± 8.4 and 47.7 ± 2.6 in vehicle- and clozapine treated cells, respectively (d(iii)). 
Combined data each from n = 3 × 44 experiments, with the average value from each experiment shown, error 
bars represent ± S.E.M.
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Importantly, binding of eticlopride, nemonapride and clozapine was without effect on distances between these 
specific residue pairs (Fig. 10 and Supplemental Figure 3).
Interestingly, based on mutagenesis studies, we have previously proposed residues from each of TMD 
IV-TMD V and TMD I-TMD II helices as generating active interfaces in hD3R dimers and tetramers20 based on 
the available eticlopride-bound hD3R atomic level structure. The spiperone-induced alteration in the distance 
between residues of TMD IV and TMD V and haloperidol-induced alteration in the distance between TMD I and 
TMD II residues, may be integral to why spiperone and haloperidol but not the other ligands produced reduced 
levels of hD3R dimers/oligomers.
Figure 8. Treatment with spiperone does not alter the quaternary organization of hD3R-Asp110Ala. hD3R-
Asp110Ala-mEGFP was expressed constitutively in Flp-In T-REx 293 cells. Confocal images were collected 
across the midsection (a(i)) and from the basolateral membrane (a(ii)) of cells. Scale bar = 20 μm. (b) 
Fluorescence intensity corresponding to mEGFP was measured in non-transfected (circle), hD3R-mEGFP- 
(square) or hD3R-Asp110Ala -mEGFP (triangle) expressing Flp-In T-REx 293 cells. Data from n = 3 experiments, 
with the average value from each experiment shown, error bars represent ± S.E.M. (c) Specific binding of [3H]
spiperone (5 nM) was assessed in either non-transfected (circle), hD3R-mEGFP (square) or hD3R-Asp110Ala 
-mEGFP (triangle) expressing Flp-In T-REx 293 cells. Data from n = 3 experiments with the average value from 
each experiment shown, error bars represent ± S.E.M. ns = not significant; ***p < 0.001 when compared to 
non-transfected Flp-In T-REx 293 cells. (d) QB MEU were assessed in individual RoI and plotted against the 
number of receptors per µm2 at the cell surface. Black circles, untreated hD3R-mEGFP expressing cells; Dark grey 
circles, spiperone treated hD3R-mEGFP expressing cells; Light grey circles, untreated hD3R-Asp110Ala-mEGFP 
expressing cells; Open circles, spiperone treated hD3R-Asp110Ala -mEGFP expressing cells. (e) Quaternary 
arrangement of hD3R-mEGFP or hD3R-Asp110Ala-mEGFP receptors expressed as QB MEU value in not 
treated cells ((NT) 1.36 ± 0.02 and 1.31 ± 0.03, respectively) and cells treated with spiperone ((S) 1.09 ± 0.03 
and 1.34 ± 0.03, respectively). Combined data from n = 3 × 25 measurements, error bars represent ± S.E.M. 
ns = not significant; ***p < 0.001 when compared to the indicated sample. (e) Assessment of percentage of 
RoIs containing predominantly hD3R-mEGFP or hD3R-Asp110Ala -mEGFP dimers/oligomers in untreated 
((NT) 40.0 ± 6.1% and 38.7 ± 3.5%, respectively) or treated with spiperone ((S) 10.7 ± 3.5% and 37.3 ± 3.5%, 
respectively). Combined data from n = 3 × 25 experiments, error bars represent ± S.E.M., ns = not significant; 
**p < 0.01 when compared to the indicated sample.
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Discussion
The idea that members of the class A sub-family of GPCRs can form dimers and/or oligomers has been hypothe-
sized and tested for a considerable period4. Key questions that remain uncertain or unanswered include whether 
such complexes are stable or transient, if the extent of oligomerization is determined, at least in part, by receptor 
expression levels, and to what extent the steady-state level of such quaternary organization can by altered by the 
binding of receptor ligands. Recently, the first two of these issues have begun to be addressed. Using single mol-
ecule tracking studies clear evidence has now been provided that interactions between individual monomers, of 
at least muscarinic acetylcholine receptor subtypes35, 36, the dopamine D2 receptor37 and the N-formyl peptide 
receptor38, 39, are transient. Moreover, consistent with Mass-Action, for both the β1- and β2-adrenoceptors40, the 
serotonin 5-HT2C receptor41, the dopamine D2 receptor37 and the opsin receptor42 quaternary complexity has 
Figure 9. The effect of spiperone on hD3R quaternary arrangement is reversible and cannot be attributed 
to ligand inverse agonism or ligand-induced differences in receptor mobility. (a) Flp-In T-REx 293 hD3R-
mEGFP clone 2 cells were untreated (NT), treated with spiperone for 2 hours (spiperone (2 h)) or treated 
with spiperone for 2 hours and washed in growth medium at 37 °C for 4 hours (spiperone washout). QB MEU 
were assessed in individual RoI and plotted against the number of hD3R-mEGFP per µm2 at the cell surface. 
Dark grey circles, untreated cells (NT); Black circles, cells treated with spiperone for 2 h; Light grey circles, cells 
treated with spiperone for 2 h and washed in growth medium for 4 h (a(i)). Quaternary organization of hD3R–
mEGFP receptor was expressed as QB MEU value and was equal to 1.39 ± 0.02, 1.08 ± 0.01 and 1.35 ± 0.01 
in vehicle-, spiperone- and spiperone-treated followed by washout of the ligand cells, respectively (a(ii)). 
RoIs containing predominantly dimers/oligomers corresponded to 21.3 ± 1.5, 2.00 ± 0.6 and 18.3 ± 0.7% in 
vehicle-, spiperone- and spiperone-treated followed by washout cells, respectively (a(iii)). Combined data from 
n = 3 × 44 experiments (performed in parallel), with the average value from each experiment shown, error 
bars represent ± S. E.M., ***p < 0.001, when compared to the indicated treatment, ns = not significant. (b) 
Membranes from Flp-In T-REx 293 hD3R + Cys352Ile Go1 cells maintained in the absence (−Dox) or presence 
of 100 ng.ml−1 doxycycline (+Dox) were used to measure basal [35S]GTPγS binding (−Dop) and the effect of 
10 μM dopamine (+Dop). Addition of receptor saturating concentrations of spiperone, haloperidol, eticlopride, 
nemonapride or clozapine did not reduce the basal level of [35S]GTPγS binding. Combined data from n = 3 
experiments, error bars represent ± S. E.M., ***p < 0.001, ns = not significant when compared to basal (+Dox 
−Dop). (c) Analysis of the recovery of fluorescence intensity after mEGFP photobleaching at the basolateral 
membrane of Flp-In T-REx 293 hD3R-mEGFP clone 2 cells untreated (black) or treated with receptor saturating 
concentration of spiperone (red) or eticlopride (green). Combined data from n = 11 experiments, error bars 
represent ± S.E.M.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7: 2134  | DOI:10.1038/s41598-017-02249-3
been reported to increase with higher levels of expression of the receptor. Although this is in contrast to earlier 
conclusions for both the dopamine D2 receptor5–7 and the serotonin 5-HT2c receptor43 where the reported extent 
of dimerization remained constant across expression ranges of at least 10 fold, herein we provide further support 
of the importance of Mass-Action in this process by showing that quaternary complexity of the D3R also increases 
with receptor expression level. To explore this, we took advantage that a number of previous studies had indicated 
that treatment of cells expressing a GPCR of interest with sodium butyrate can result in up-regulation of receptor 
levels30, 31. Overnight treatment of cells stably expressing D3R-mEGFP with sodium butyrate, that resulted in less 
than a doubling of receptor number, was associated with a marked increase in the proportion of RoIs examined in 
which dimeric/oligomeric organization of the receptor was dominant. This approach eliminated potential caveats 
of effects of clonal variability in determining the extent of receptor structural complexity.
In the current experiments hD3R was expressed in the HEK293-based cells at levels, based on the specific 
binding of [3H]spiperone, between 500–1500 fmol per mg membrane protein in the three individual clones 
used. Clone 2 expressed the receptor to the highest levels. Based on surface area of these cells, determined to 
be 5235 µm2 (see ‘Experimental’ for calculation of this value), the amount of membrane protein generated 
per 106 cells, and the apparently uniform distribution of the receptor within the plasma membrane as seen in 
cross-sectional confocal images, this yielded a predicted average receptor density as some 81 receptors per µm2. 
This value was both similar to estimates provided within the SpIDA software and, importantly, was centrally 
located within the range of molecules per μm2 of P + M mEGFP used for the calibration studies, in which no 
appearance of apparent dimers of P + M mEGFP was observed that could have reflected simple molecular prox-
imity due to high levels of protein expression.
One of the major outstanding issues in considering class A GPCR quaternary structure and its implications 
is the effect, if any, of ligands on receptor organizational structure. This has been a much discussed and debated 
topic44–46 with at least as many reports indicating that ligands have little or no effect than those which argue 
Figure 10. Molecular dynamics simulations indicate that binding of spiperone and haloperidol induces 
distinct conformational changes in the tertiary structure of hD3R. Molecular dynamics simulations of the 
hD3R apo-protein, or hD3R bound with eticlopride, spiperone, haloperidol, clozapine or nemonapride were 
run for 500 ns. (a) Comparison of the distances between the residues located at positions 1.35 and 2.65 in TMD 
I-TMD II, 3.40 and 6.44 in TMD III-TMD VI and 4.50 and 5.50 in TMD IV-TMD V in the hD3R is shown. 
Data are means ± SEM from n = 3 experiments, with the average value from each experiment shown, *p < 0.05; 
**p < 0.01 when compared with the apo-protein. See Results for details of quantification. (b) Representation 
of the tertiary structure of the receptor at the end of this period. The distances between residues within helices 
(calculated as distance between the pairs of c-alphas denoted above) are shown.
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differently47, 48. In the current studies, we add to and extend this topic greatly. Firstly, we show that certain antag-
onists with high affinity for the D3R strongly favor reduction in quaternary complexity of this receptor and pro-
mote its monomerization. Such an effect may provide a rational for why Tabor et al.37, reported very modest levels 
of D3R dimerization as the analysis was based on the binding of a fluorescent antagonist to the receptor. Ligands 
that promoted monomerization of the D3R comprised the chemically-related butyrophenones, spiperone and 
haloperidol. However, this was not a universal effect produced by binding of any antagonist with high affinity 
for the D3R. Interestingly, among ligands lacking this effect was the benzamide eticlopride, the ligand used to 
enhance stabilization and crystallization of the D3R in the studies of Chien et al.22. Perhaps not surprisingly in 
this regard given its chemical relatedness to eticlopride, nemonapride also failed to alter the balance between 
D3R monomers and dimers/oligomers, and this was also the case for the tricyclic dibenzodiazepine and atypical 
antipsychotic drug clozapine.
We have previously noted that certain antagonists of the 5-HT2C receptor also favor monomerization of that 
receptor, but in those studies we did not identify antagonist ligands that did not have such an effect41. By contrast, 
in studies on the muscarinic M1 receptor we showed that M1-subtype selective antagonists, including pirenze-
pine and the closely related ligand telezepine, but not subtype non-selective antagonists, including the prototypic 
anti-muscarinic drug atropine, also altered receptor quaternary structure at steady-state27. Interestingly, in this 
case pirenzepine increased the proportion of receptor dimer/oligomers. To provide a potential molecular expla-
nation of the selective effects of spiperone and haloperidol compared to eticlopride, nemonapride and clozapine, 
we exploited a combination of ligand docking studies and molecular dynamics simulations. Based on a study of 
long time-scale simulation of haloperidol and clozapine in complex with hD2R and hD3R23, we reproduced such 
dockings, inferred the docking of spiperone and nemonapride and ran 500 ns molecular dynamic simulations. 
Spiperone and haloperidol share a fluoro-butyrophenone moiety, which is positioned deeply in the TMD bundle 
and located close to TMD V. Our dynamics simulation with spiperone observed this moiety to reach slightly more 
deeply into the bottom of the binding site than haloperidol, in proximity to residues Pro5.50, Ile3.40 and Phe6.44. 
This group of residues are part of the “transmission switch” that provides early stage activation of GPCRs. Unlike 
spiperone, haloperidol has a chloro-phenyl moiety which protrudes between the external side of TMD II and 
TMD III, altering the relative distance between these helices. Thomas et al.23, also considered the mode of binding 
of clozapine to D3R, which unlike haloperidol and spiperone did not promote monomerization of the D3R. Here, 
the mode of binding was very different from that observed for haloperidol as clozapine has a compact chemi-
cal scaffold, more akin to the D3R-co-crystallized ligand eticlopride. Like clozapine, nemonapride has a more 
compact scaffold as compared to spiperone or haloperidol. Docking showed it to bind in a more superficial way 
than the other ligands and we did not observe any significant changes in distances between TMDs. Recently a 
mutagenesis analysis of TMDs in D3R dimers concluded that residues from within TMD IV and TMD V provide 
a key interface20. As the predominant binding pose of spiperone in the receptor results in alterations in this region 
it may provide a molecular explanation for both destabilization of D3R dimers and for the selectivity of this ligand 
in exerting this action. Interestingly, while our molecular dynamics simulations indicate that binding of spiperone 
significantly increases the distance between TMD IV and TMD V at the extracellular face of the D3R compared 
to the apo-protein in the absence of a ligand, such an effect was not produced by binding of any other ligand con-
sidered in this study. Nontheless, previous mutagenesis studies also highlighted a potential key role for residues 
near the extracellular face of TMD I and TMD II in the stabilization of the second D3R dimeric configuration. 
Thus it is of importance that our dynamics simulations indicated that binding of spiperone-related haloperidol 
significantly increases the distance between TMD I and TMD II at the extracellular face of the D3R compared to 
the apo-protein. Although these are inherently predictions, further application of this combination of approaches, 
linked to both further mutagenesis studies and, indeed, medicinal chemistry, are likely to help validate or repu-
diate this putative basis of selective ligand regulation of D3R quaternary organization. These studies emphasize 
that chemically different ‘antagonist’ ligands can potentially stabilize distinct, inactive states of a GPCR. Given 
that it is now widely accepted that different ‘agonist’ ligands can stabilize detectably different states of a GPCR, 
such outcomes should not be considered surprising and further illustrate that the binding of different ligands to 
their receptor targets must be considered as producing individual and unique complexes that may alter functional 
outcomes and the effectiveness of different drugs in a clinical context.
Although studies are limited to approaches like the detection of SDS-resistant ‘dimers’ in immunoblotting 
studies, Wang et al.49, have reported increases in the proportion of D2-receptor dimers in striatal tissue both in 
schizophrenia patients and also in an amphetamine-induced sensitized state in a rodent model. There are also 
reported effects on levels of the D2 receptor ‘high agonist affinity’ state in similar situations50. Although requiring 
a great deal of further analysis it is of interest, therefore, that treatment with haloperidol reverses the chronic 
amphetamine-induced development of the D2 receptor ‘high agonist affinity’ state50. This supports the clinical 
relevance of D2 receptor oligomerization. Although focus in the above noted studies was on the D2-receptor, 
anti-psychotic agents generally also interact effectively with D3R. It would be of interest, therefore, to know if 
drugs such as eticlopride and clozapine mimic or not the effects of haloperidol in such models.
With increasing attention being paid to differences in the clinical effectiveness of drugs that nontheless inter-
act with the same receptor or suite of molecular targets, it will now be important to examine more closely whether 
variation in the capacity to alter the quaternary organization of such drug receptors might help to differentiate 
and classify ligands as regards their functional and therapeutic profiles.
Experimental Proceedures
Materials. General laboratory chemicals, as well as poly- D-lysine, dopamine, haloperidol, spiperone, 
(+)-butaclamol, clozapine, sodium butyrate and both anti-tubulin and secondary horseradish peroxidase con-
jugated antibodies were from Sigma-Aldrich (Poole, UK) or Fisher Scientific (Leicester, UK). Otherwise, DNA 
restriction endonucleases, calf intestinal alkaline phosphatase, T4 DNA polymerase and T4 ligase were from 
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New England Biolabs (Hitchin, UK). Primers utilized in molecular biology procedures were provided by MWG 
Operon (Acton, UK). Wizard Plus SV Miniprep kit was from Promega (Southampton, UK). NuPage Novex pre-
cast 4–12% Bis-Tris gels and NuPage MOPS SDS running buffer were from Invitrogen (Paisley, UK). QIAfilter 
Plasmid Maxi Kit, PCR purification kit and QIAquick gel extraction kit were from Qiagen (Crawley, UK). 
Agarose was from Flowgen Biosciences (Nottingham, UK). The anti-GFP antiserum was generated in-house. 
Complete protease inhibitors mixture was from Roche Diagnostics (Burgess Hill, UK). ECL reagent was pur-
chased from Pierce (Tattenhall, UK). [3H]spiperone and [35S]GTPγS were from Perkin Elmer (Chalfont Road, 
UK). Eticlopride and nemonapride were from Tocris (Bristol, UK). Hank’s Balanced Salt Solution (HBSS) was 
from Life Technologies (Paisley, UK).
DNA constructs. Enhanced Green Fluorescent Protein incorporating an A206K mutation to reduce any 
tendency for the fluorescent protein to homodimerize (mEGFP)28 was a gift of Dr K. Herrick-Davis (Albany, New 
York). In order to localize mEGFP to the plasma membrane a palmitoylation-myristolation (P-M) sequence was 
added to the amino terminal of the fluorescent protein, as in refs 27 and 42. hD3R-mEGFP construct was made 
by subcloning PCR amplified hD3R between the KpnI and SmaI sites of pEGFPN-1 plasmid (Takara Bio Europe/
Clontech, Saint-Germain-en-Laye, France). The ‘QuikChange’ method (Stratagene, Agilent Technologies, Santa 
Clara, CA) was used to introduce the alteration Asp110Ala into hD3R-mEGFP. Template DNA was digested with 
DpnI to leave only the newly synthesized mutated plasmid. All the constructs were verified by sequencing.
Cell lines. All cells were maintained in a humidified incubator with 95% air and 5% CO2 at 37 °C. Parental Flp-In 
T-REx 293 cells (Invitrogen, Paisley, UK) were maintained in DMEM (high glucose) supplemented with 10% 
(v/v) fetal calf serum, 100 U.ml−1 penicillin, 0.1 mg.ml−1 streptomycin, 10 μg.ml−1 blasticidin and 100 μg.ml−1 
zeocin. Flp-In T-REx 293 P-M-mEGFP cells were maintained in DMEM (high glucose) supplemented with 10% 
(v/v) fetal calf serum, 100 U.ml−1 penicillin, 0.1 mg.ml−1 streptomycin, 10 μg.ml−1 blasticidin and 200 μg.ml−1 
hygromycin. Flp-In T-REx 293 hD3R-mEGFP cells were maintained in DMEM (high glucose) supplemented with 
10% (v/v) fetal calf serum, 100 U.ml−1 penicillin, 0.1 mg.ml−1 streptomycin, 10 μg.ml−1 blasticidin and 1 mg·ml−1 
G418.
Stable cell line generation. Inducible Flp-In T-REx 293 stable cell lines able to express P-M mEGFP 
were generated as described by ref. 41. Flp-In T-REx stable cell lines able to express hD3R-mEGFP or 
hD3R-Asp110Ala-mEGFP constitutively were generated by transfecting parental Flp-In T-REx cells with 
hD3R-mEGFP or hD3R-Asp110Ala-mEGFP and antibiotic-resistant clones selected using 1 mg·ml−1 G418.
mEGFP fluorescence intensity measurement. Cells were grown to 100,000 cells per well in solid black 96-wells 
plates (Corning) coated with 0.1 mg per ml poly-D-lysine. On the day of the experiment, cells were washed 
with HBSS (3 times on ice). Plates with 100 µl per well HBSS were then read on a PheraStar FS (BMG Labtech, 
Ortemberg, Germany) fluorescent intensity compatible reader and the emission signal from the mEGFP (520 nm) 
was recorded after excitation at 485 nm.
Cell treatments. For antagonist treatments and sodium butyrate studies cells were incubated with the appropri-
ate concentration of compound or salt for 16 h at 37 °C. For the short term treatment studies cells were treated 
with 10 µM spiperone for 2 h at 37 °C and then washed six times with medium before being incubated for a further 
4 h at 37 °C before confocal images were collected.
Cell lysate preparation. Cells were harvested in ice cold phosphate buffered saline (PBS) (120 mM NaCl, 25 mM 
KCl, 10 mM Na2HPO4 and 3 mM KH2PO4, pH7.4) and lysed in lysis buffer (150 mM NaCl, 0.01 mM Na2HPO4, 
2 mM EDTA, 0.5% n-dodecyl-ß-D-maltoside (DDM), 5% glycerol and supplemented with ‘Complete’ protease 
inhibitors mixture) on a rotating wheel for 30 min at 4 °C. Samples were then centrifuged for 15 min at 21000 × g 
at 4 °C, aliquoted and stored at −20 °C until required.
Immunoblotting assays. Cell lysate samples prepared as above were diluted to a final concentration of 2 mg.ml−1 
in lysis buffer. Samples were prepared by the addition of SDS-PAGE sample buffer and heated to 65 °C for 5 min. 
5 μg of protein from each sample was loaded into wells of 4 to 12% BisTris3 gels and subjected to SDS-PAGE anal-
ysis using NuPAGE MOPS SDS running buffer. After separation, the proteins were electrophoretically transferred 
onto nitrocellulose membrane, which was then blocked (5% fat-free milk powder in PBS) for 1 h at room temper-
ature on a rotating shaker. The membrane was then incubated with appropriate primary antibody in 5% fat-free 
milk powder in PBS supplemented with 0.1% Tween 20 (PBS-Tween) overnight at 4 °C on a rotating shaker. 
Anti-GFP antiserum was diluted 1:10000 and anti-α-tubulin antiserum diluted 1:5000. Subsequently, the mem-
brane was washed (3 × 10 min with PBS-Tween) and then incubated for 1 h with the appropriate secondary anti-
body (horseradish peroxidase-linked rabbit anti-goat IgG or horseradish peroxidase-linked sheep anti-mouse) 
diluted 1:10000 in 5% fat-free milk powder in PBS-Tween. After washing (3 × 10 min with PBS-Tween), proteins 
were detected by enhanced chemiluminescence according to the manufacturer’s instructions.
Cell membrane preparation. Cells were harvested in ice cold PBS and pellets of cells frozen at −80 °C, for a 
minimum of 30 min. These were subsequently thawed and resuspended in ice-cold 10 mM Tris, 0.1 mM EDTA, 
pH 7.4 (TE buffer) supplemented with Complete protease inhibitors mixture. Cells were homogenized on ice by 
40 strokes of a glass-on-Teflon homogenizer followed by centrifugation at 200 × g for 10 min at 4 °C to remove 
unbroken cells and nuclei. The supernatant fraction was transferred to ultracentrifuge tubes and subjected to cen-
trifugation at 90000 × g for 45 min at 4 °C. The resulting pellets were resuspended in ice-cold TE buffer and passed 
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through a 25-gauge needle 3 times before being assessed for protein concentration. Membrane preparations were 
then aliquoted and stored at −80 °C until required.
[3H]spiperone binding studies on membrane preparations. Both single concentration binding studies and satura-
tion binding curves were established by the addition of 5 µg of membrane protein to assay buffer (20 mM HEPES, 
6 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 40 μM ascorbic acid) containing either a single, near saturating, con-
centration (5 nM) or varying concentrations (0.019–14 nM) of [3H]spiperone in 200 µl final volume. Non-specific 
binding was determined by the addition of 10 μM (+)-butaclamol. Reactions were incubated for 2 h at 30 °C and 
terminated by rapid vacuum filtration though GF/C glass fiber filters followed by three washes with ice-cold PBS. 
The level of radioactivity associated with the filters was quantified using a TriCarb 2810 Tr scintillation counter. 
Competition binding assays were carried out in a similar way, but with a constant concentration of [3H]spiperone 
(1 nM) and the addition of a range of concentrations of ligands of interest. Data were analysed using Graphpad 
Prism 5.03 (Graphpad Inc, CA, USA).
[3H]spiperone binding studies on intact cells. Cells were grown to 100000 cells per well in solid white 96-wells 
plates (Corning) coated with 0.1 mg per ml poly-D-lysine. On the day of the experiment cells were washed 
with HBSS (3 times on ice) and 5 nM [3H]spiperone was added to appropriate wells containing or not 10 μM 
(+)-butaclamol to determine non-specific binding in 100 µl final volume. Plates were incubated for 4 h at 4 °C 
and the reactions were terminated by removal of the binding mixture followed by washing with 4 × 200 μl per well 
ice-cold HBSS. One hundred microliters per well microscint 20 (Perkin Elmer Life Sciences) was added and the 
plates were sealed before overnight incubation at room temperature on a rapidly shaking platform. Bound ligand 
was determined using a Packard Topcount NXT (Perkin Elmer Life Sciences). Using the specific binding per well 
and number of cells per well, receptor copy per cell was determined.
[3H]spiperone dissociation studies. Were carried out according to the method of the “infinite dilution” achieved 
by abundantly washing cells and resuspending them in ligand-free buffer. In details, cells were plated at 70,000 
cells per well in 96-well plates 24 h before the assay. On the day of the experiment, cells were washed with Hanks’ 
balanced salt solution (HBSS) 3 times and then 0.5 nM [3H]spiperone was added to each well in the absence or 
presence of 10 μM (+)-butaclamol to determine non-specific binding, in 100 µl final volume. Plates were incu-
bated for 1 h at 37 °C and the reactions was terminated by five washes with HBSS. To monitor radioligand disso-
ciation 100 µl per well HBSS was added to each well and this was replaced with 100 µl per well Microscint 20 at 
various times.
[35S] GTPγS Binding Assays. Cell membranes (10 μg) were incubated in 900 μl of buffer (20 mM HEPES, 
100 mM NaCl, 6 mM MgCl2, 40 μM ascorbic acid, pH 7.4) containing 1 μM GDP, 10 μM dopamine (where indi-
cated) and receptor saturating concentrations of the appropriate antagonist. All experiments were performed 
in triplicate. The reaction was initiated by the addition of cell membranes and incubated at 30 °C for 30 min. A 
100-μl volume of [35S]GTPγS (0.1 nM final concentration) was then added, and the incubation was continued 
for a further 30 min. The reaction was terminated by rapid filtration with a Brandel cell harvester and three 
4-ml washes with ice-cold phosphate-buffered saline. Radioactivity was determined as described for saturation 
analysis.
Spatial Intensity Distribution Analysis (SpIDA). Was carried out essentially as described in refs 27 and 41. All 
RoI measurements were selected from the basolateral membrane surface. Unbiased RoI selection was evaluated 
for each experimental group by normalizing the quantified mean fluorescence intensity of the whole background 
corrected image to the mean fluorescence intensity measured from each RoI analysed within that image. The 
fraction range varied from 0.93 ± 0.02 (spiperone treated sample) to 0.80 ± 0.06 (nemonapride treated sample) 
and in no case was the fraction values significantly different when compared with those obtain for the untreated 
sample indicating that the total receptor population had been analyzed competently and no unbiased selection 
had occurred. MEU values for hD3R-mEGFP were measured by normalizing their quantified QB values to aver-
age QB values measured from the P-M-mEGFP construct using exactly the same laser power as used to excite 
the hD3R-mEGFP construct. To distinguish between monomeric and dimeric/oligomeric hD3R-mEGFP species, 
P-M-mEGFP MEU occurrence/frequency x-y graphs (MEU bin size = 0.1) were plotted for each MEU value 
measured during excitation with laser power set to 2 or 6%. Such plots revealed a symmetrical distribution of the 
values and Graphpad Prism normality tests indicated the distributions were Gaussian (see Results and Statistical 
analyses). The data from each frequency x-y plot measured using 2 or 6% laser power were combined as this 
range of excitation settings was required to illuminate the hD3R-mEGFP optimally at differing expression levels 
without erroneous detector pixel saturation occurring. From this combined plot, an MEU value of 1.406, (which 
represented 95.44% of the data set, falling within the mean + 2 standard deviations), was set as a threshold to 
distinguish between monomeric and larger complexes in studies where individual MEU values exceeded 1.406.
Calculation of receptor density at the cell surface by SpIDA. SpIDA software also reports the mean fluorescent 
intensity for each RoI analyzed. The number of hD3R-mEGFP or P-M-mEGFP molecules per μm2 (density) was 
measured by dividing the mean fluorescent intensity value by the quantified monomeric QB value.
Calculation of Flp-In T-REx 293 cell surface area. 3D stacks of Flp-In T-REx 293 cell expressing the mEGFP 
tagged 5-HT2C receptor at the membrane surface41 were recorded on a Zeiss Exciter confocal using a 63 x oil 
immersion Plan Apochromat objective lens using a step z size of 0.26 microns. The 3D stacks were loaded into the 
software program Autodeblur/Autovisualise, (version 9.3.6, Autoquant Imaging, Watervliet, NY), and receptor 
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fluorescence within the 3D stack for each individual image was segmented using the adaptive thresholding tool to 
resolve mEGFP-tagged receptor fluorescence from background autofluorescence. The total surface area was then 
subsequently quantified using the surface area volume tool.
Fluorescence recovery after photobleaching (FRAP). Image Acquisition: Fluorescence recovery after photobleach-
ing (FRAP) experiments were performed using a Zeiss 510 Exciter laser scanning confocal equipped with a 
63x/1.4 NA Plan Apochromat oil-immersion objective. The 488 nm argon laser line was used to sequentially 
excite mEGFP and the image format size was set to 256 × 256 to speed up sequential 2.5 s time lapse image col-
lection. To minimise mEGFP fluorescence photobleaching the 488 nm laser line was set to 4% for acquisition 
of the pre-bleach and post-bleach recovery images. Bleaching was performed on the basolateral membrane of 
cells by setting the laser power to 100% and the RoI bleached spot size was set to 3 µm in diameter. 5 pre-bleach 
images and 44 recovery images were acquired to quantify the degree of fluorescence recovery after the laser RoI 
photobleaching event. FRAP analysis: Time lapse stack images generated from each experimental group were 
imported into Metamorph software, (version 7.8), and auto-aligned to correct for x-y drift. For each experimental 
image stack set, a circular RoI was drawn within the observed bleached area, (RoI Fs), and the average fluores-
cence intensity within the RoI Fs was quantified for each individual image within the stack to quantify the average 
level of fluorescence before and after photobleaching. The degree of background autofluorescence was quantified 
similarly by drawing an RoI in an area where no cell fluorescence was expressed, (RoI Fb). To monitor the native 
photobleaching rate (r), for each FRAP experiment, a control RoI was drawn on a non-bleached cell within the 
time lapse image series. The photobleaching rate (r) was then quantified by comparing the average fluorescence 
intensity of the control RoI at time zero, (Fc0), with the corresponding measured average fluorescence inten-
sity at the end of the experiment, (Fc), e.g. r = Fc/Fc0. The average fluorescence intensity of the Fs RoI for each 
stack image was corrected for the degree of native photobleaching and background autofluorescence for each 
FRAP experiment as follows: F = (RoI Fs − RoI Fb)/r. The F data was the normalized, (0–100%), and the recovery 
half-life and mobile fraction were quantified using the Graphpad Prism software one-phase exponential equation.
Computational methods. A modification of the crystal structure of hD3R, in complex with eticlopride, 
(PDB code: 3PBL)22 was used to build all the D3R–ligand complexes or the apo-protein models. As the N-terminal 
of TMD I in hD3R crystals is about 2 helix turns shorter than all other class A GPCR structures released to date, 
Modeller 9v851 was used to model a TMD I as long as observed in the turkey ß1-adrenoceptor52. Haloperidol and 
clozapine where docked as by Thomas et al.23, while nemonapride and spiperone were docked into the modified 
hD3R crystal structure using the Autodock Vina tool53. All docking poses were visually inspected and two more 
frequent docking possibilities were observed. In the case of nemonapride they were similar and two dynamics 
simulation converged on the first poses, while in the case of spiperone in the first pose the fluoro-butyrophenone 
moiety of spiperone was deeply buried in the binding pocket, in a similar conformation to the one described by 
Thomas et al.23 for the hD3R-haloperidol complex (which shares this chemical feature with spiperone) whilst in 
the second the fluoro-butyrophenone moiety of spiperone faces the extracellular side of TMD 1. As both these 
conformations have been reported in the literature we employed molecular dynamics simulations to assess which 
was more stable. This showed the only conformation stable in a 500 ns molecular dynamics simulations was 
that akin to that reported by Thomas et al. for haloperidol23. On this basis we selected this as the docking pose. 
Ligand-hD3R complexes were embedded in a lipid bilayer (187 molecules of POPC) with explicit solvent (14067 
water molecules) and counter-ions (58 Na+ and 67 Cl−). Model systems were energy minimized and subsequently 
subjected to a 27 ns molecular dynamics equilibration, with incremental positional restraints on non-hydrogen 
atoms, main chain, loop free and the Cα atoms of the receptor, to remove possible voids present in protein/lipids 
or protein/water interfaces. These restraints were released and 500 ns MD trajectories were produced at constant 
pressure and temperature, using the particle mesh Ewald method to evaluate electrostatic interactions with the 
GROMACS software54 v5.1, the AMBER99SB force field for the amino acids, and Berger parameters for POPC 
lipids, using the protocol previously described55. Analyses of the trajectories were made using VMD v1.9.356.
Statistical analyses. Variation in receptor number among the three different clones considered or produce 
by treatment with ligands was assessed by 1-way ANOVA with the use of Bonferroni’s or Dunnett’s test for multi-
ple comparisons as appropriate. Variation in receptor number produced by treatment with sodium butyrate was 
assessed by Student’s t test. Variation in mean of QB was assessed by Student’s t test or 1-way ANOVA with the use 
of Dunnett’s test for multiple comparisons as appropriate. Normality distributions of recovered QB values defined 
as MEUs were assessed by of D’Agostino and Pearson (at p > 0.05) and by skewness and Kurtosis assessments. 
Distributions that failed the normality assessment (at p < 0.05) were considered to be non-Gaussian. Variation 
in [3H]spiperone binding was assessed by 1-way ANOVA with the use of Bonferroni’s or Dunnett’s test for mul-
tiple comparisons as appropriate. Variation in [35S]GTPγS binding was assessed by 1-way ANOVA with the use 
of Dunnett’s test for multiple comparisons. Variation in the half-time and mobile fraction in FRAP experiments 
were assessed by 1-way ANOVA with the use of Bonferroni’s for multiple comparisons. Variation in the distances 
between residues within helices in molecular dynamics simulations were assessed by 1-way ANOVA with the use 
of Tukey’s for multiple comparisons.
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